Compare Abbott Laboratories (ABT) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Invesco S&P 500 Momentum ETF — how do they compare? Abbott Laboratories trades at $109.55 (market cap $187.95B), while Invesco S&P 500 Momentum ETF trades at $149.43. The key difference: Abbott Laboratories pays a 2.32% dividend while Invesco S&P 500 Momentum ETF pays none, and Invesco S&P 500 Momentum ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | SPMO | |
|---|---|---|
Market Cap | $187.95B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $136.62 | $161.66 |
52-Week Low | $82.57 | $107.84 |
Enterprise Value | $214.96B | — |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.
Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.
SPMO (Invesco S&P 500 Momentum ETF) trades at $149.69, up 0.4% with strong bullish momentum indicators. The ETF has demonstrated exceptional 2026 performance with 26% returns, significantly outperforming the S&P 500 while maintaining lower drawdowns. Technical analysis shows bullish moving averages but neutral oscillators, with RSI_6 at 88.22 suggesting potential overbought conditions. Recent institutional interest includes Alpha Zero LLC increasing its position by 6.4% to $10.73 million in Q1 2026.
The outlook remains positive given SPMO's momentum-driven strategy and concentrated tech exposure (55% weighting), particularly benefiting from AI-driven growth. However, risks include higher volatility during sector rotations and downside vulnerability if momentum factors reverse. The ETF's 0.13% expense ratio provides cost efficiency for momentum exposure, but investors should monitor concentration risks in technology holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
